GlassScriptPhysician profile
Kazue Okajima
NPI 1568710010
$3,683.49
in general payments reported to CMS, 2019-2025
17 companies · $122 in 2025
The $122 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $558 · 2020: $254 · 2021: $365 · 2022: $470 · 2023: $552 · 2024: $1,363 · 2025: $122.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $1,053 · Food and Beverage: $984.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $1,053.01 |
| Food and Beverage | $983.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Heartflow, INC. | $1,704.52 | 2022-2024 | Ffrct |
| Abbott Laboratories | $508.93 | 2020-2025 | Triclip |
| Edwards Lifesciences Corporation | $233.91 | 2019-2023 | |
| Pfizer INC. | $214.42 | 2020-2021 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $214.38 | 2019 | |
| Actelion Pharmaceuticals US, INC. | $160.03 | 2022-2023 | Uptravi, Opsumit |
| Novartis Pharmaceuticals Corporation | $157.55 | 2019-2021 | |
| Medtronic, INC. | $115.45 | 2023 | Corevalve Evolut R |
| E.R. Squibb & Sons, L.L.C. | $105.02 | 2019-2023 | Eliquis |
| Amgen INC. | $89.32 | 2019 | |
| Boston Scientific Corporation | $52.50 | 2022 | |
| Medtronic Vascular, INC. | $33.08 | 2020 | |
| Cvrx, INC. | $23.40 | 2023 | Barostim Neo System |
| Janssen Pharmaceuticals, INC | $23.08 | 2021 | |
| W. L. Gore & Associates, INC. | $18.21 | 2021 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lantheus Medical Imaging, INC. | $17.39 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $12.30 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kazue Okajima listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.